Christopher Chapple

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Health Publishing (General Urology)
    Ineligible company:
    Astellas
    Date added:
    Date updated:
    08/08/2021
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Allergan
    Date added:
    Date updated:
    08/08/2021
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (General Urology)
    Ineligible company:
    Allergan
    Date added:
    Date updated:
    08/08/2021
  • Attribution:
    Self
    Type of financial relationship:
    Meeting Participant or Lecturer (General Urology)
    Ineligible company:
    Allergan
    Date added:
    Date updated:
    08/08/2021
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Contura
    Date added:
    Date updated:
    08/08/2021
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Pierre Fabre
    Date added:
    Date updated:
    08/08/2021
  • Attribution:
    Self
    Type of financial relationship:
    Meeting Participant or Lecturer (General Urology)
    Ineligible company:
    Luoin Pharma
    Date added:
    Date updated:
    08/08/2021
  • Attribution:
    Self
    Type of financial relationship:
    Leadership Position (General Urology)
    Ineligible company:
    European Association of Urology
    Date added:
    Date updated:
    08/08/2021
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Urovant Sciences
    Date added:
    Date updated:
    08/08/2021
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Symimetics
    Date added:
    Date updated:
    08/08/2021

Pages

Return to Contemporary Pharmacotherapy for OAB 2022: Monotherapy and Combined Pharmacotherapy to Optimize Treatment Webcast (2022)